These activities are supported by educational grants from Lilly, Natera Inc, Seagen Inc, and Taiho Oncology Inc.

Agenda

Each 1-hour session will be divided into topic modules focused on current management, emerging research and novel agents and strategies under active investigation for colorectal cancer. Each event will employ an identical format that will include the following elements:

• Moderator Dr Neil Love and a featured participating clinical investigator
• Discussion of participating faculty treatment recommendations
• Review of available clinical research findings
• Community oncologist video case presentations
• Interactive audience polling and extensive Q&A

MODULE 1: Current and Future Role of Therapies Targeting BRAF and HER2 in Metastatic Colorectal Cancer (mCRC)

MODULE 2: Integration of Immune Checkpoint Inhibitors into the Management of mCRC

MODULE 3: Selection and Sequencing of Therapy for Patients with Multiregimen-Relapsed mCRC

MODULE 4: Other Considerations in the Management of CRC; Promising Investigational Strategies

Target Audience
This program is intended for medical oncologists, hematologists, hematology-oncology fellows, radiation oncologists and other allied healthcare professionals involved in the treatment of colorectal cancer.

Learning Objectives

• Optimize the use of adjuvant chemotherapy for patients with localized colorectal cancer (CRC), considering the influence of various clinical and biologic factors (eg, age, performance status, stage).
• Develop a long-term plan to guide the selection and sequencing of therapies for individuals diagnosed with metastatic CRC (mCRC), considering the patient’s biomarker profile, tumor location, prior systemic therapy, symptomatology and personal goals of treatment.
• Appreciate published research data documenting the efficacy of combined BRAF/EGFR inhibition for patients with relapsed/refractory mCRC and a BRAF V600E mutation, and optimally incorporate this therapeutic strategy into the care of appropriate individuals.
• Recognize available data with anti-HER2 therapy for HER2-positive mCRC, and consider the current and future role of various approaches.
• Evaluate available data with and FDA approvals of immune checkpoint inhibitor therapies for microsatellite instability-high or mismatch repair-deficient CRC, and optimally select patients for treatment with these approaches.
• Apply available research to optimize the selection and sequencing of later-line therapeutic options for patients with multiply relapsed mCRC.
• Recall ongoing trials evaluating novel agents and strategies for patients with CRC, and use this information to refer appropriate individuals for study participation.

CE Credit
CME and ABIM MOC credit form links will be emailed to each participant within 5 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of each CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of each activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Lieu — Consulting Agreement: Amgen Inc. Dr Overman — Consulting Agreements: Bayer HealthCare Pharmaceuticals, Gritstone bio, GSK, Merck, Nouscom, Pfizer Inc, Phanes Therapeutics Inc, Roche Laboratories Inc, Takeda Pharmaceuticals USA Inc, Tempus. Dr Strickler — Advisory Committee: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, GSK, Lilly, Natera Inc, Pfizer Inc, Pionyr Immunotherapeutics, Seagen Inc, Silverback Therapeutics, Takeda Pharmaceuticals USA Inc, Viatris; Consulting Agreement: Zentalis Pharmaceuticals; Contracted Research: AbbVie Inc, Amgen Inc, AStar D3, Bayer HealthCare Pharmaceuticals, Curegenix, Daiichi Sankyo Inc, Erasca, Genentech, a member of the Roche Group, Gossamer Bio, Leap Therapeutics Inc, Lilly, Nektar, Sanofi, Seagen Inc, Silverback Therapeutics; Data and Safety Monitoring Board/Committee: AbbVie Inc, BeiGene Ltd, Pionyr Immunotherapeutics.

SURVEY PARTICIPANTS — Stacey A Cohen, MD — Advisory Committee: Bayer HealthCare Pharmaceuticals, Eisai Inc, Pfizer Inc, Taiho Oncology Inc; Consulting Agreement: Delcath Systems Inc; Contracted Research: Faeth, Natera Inc, Pfizer Inc, Tempus. Arvind Dasari, MD, MS — Advisory Committee: Bayer HealthCare Pharmaceuticals; Contracted Research: Eisai Inc, Guardant Health. Dustin Deming, MD — Advisory Committee: Bayer HealthCare Pharmaceuticals, Foundation Medicine, Illumina, Lilly, Pfizer Inc, Seagen Inc; Contracted Research: Aadi Bioscience, Arcus Biosciences, Bristol Myers Squibb, Cornerstone Pharmaceuticals Inc, Curegenix, Genentech, a member of the Roche Group, Guardant Health, Ipsen Biopharmaceuticals Inc, Lilly, Merck, Natera Inc, Pfizer Inc, Promega Corporation, Revolution Medicines, Strata Oncology, Takeda Pharmaceuticals USA Inc; Data and Safety Monitoring Board/Committee: Seagen Inc.

SERIES MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
These activities are supported by educational grants from Lilly, Natera Inc, Seagen Inc, and Taiho Oncology Inc.